Zymeworks Inc. (ZYME) stock is soaring nearly 9% in pre-market trading on Wednesday after Leerink Partners analyst upgraded the biopharmaceutical company's rating from Market Perform to Outperform.
The analyst action seems to be driving the significant upward movement in Zymeworks' stock price ahead of the regular trading session. Financial details and rationale behind the rating upgrade were not provided in the brief news summary.